PMID- 20459695
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 10
DP  - 2010 May 9
TI  - High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer 
      patients with non squamous histology.
PG  - 186
LID - 10.1186/1471-2407-10-186 [doi]
AB  - BACKGROUND: Bcl-2 promotes cell survival by inhibiting adapters needed for the 
      activation and cleavage of caspases thus blocking the proteolytic cascade that 
      ultimately dismantles the cell. Bcl-2 has been investigated as a prognostic 
      factor in non small cell lung cancer (NSCLC) patients with conflicting results. 
      METHODS: Here, we quantitatively assessed Bcl-2 expression in two large and 
      independent cohorts to investigate the impact of Bcl-2 on survival. AQUA(R), a 
      fluorescent-based method for analysis of in situ protein expression, was used to 
      measure Bcl-2 protein levels and classify tumors by Bcl-2 expression in a cohort 
      of 180 NSCLC patients. An independent cohort of 354 NSCLC patients was used to 
      validate Bcl-2 classification and evaluate outcome. RESULTS: Fifty % and 52% of 
      the cases were classified as high expressers in training and validation cohorts 
      respectively. Squamous cell carcinomas were more likely to be high expressers 
      compared to adenocarcinomas (63% vs. 45%, p = 0.002); Bcl-2 was not associated 
      with other clinical or pathological characteristics. Survival analysis showed 
      that patients with high BCL-2 expression had a longer median survival compared to 
      low expressers (22 vs. 17.5 months, log rank p = 0.014) especially in the subset 
      of non-squamous tumors (25 vs. 13.8 months, log rank p = 0.04). Multivariate 
      analysis revealed an independent lower risk for all patients with Bcl-2 
      expressing tumors (HR = 0.53, 95% CI 0.37-0.75, p = 0.0003) and for patients with 
      non-squamous tumors (HR = 0.5, 95% CI 0.31-0.81, p = 0.005). CONCLUSIONS: Bcl-2 
      expression defines a subgroup of patients with a favorable outcome and may be 
      useful for prognostic stratification of NSCLC patients.
FAU - Anagnostou, Valsamo K
AU  - Anagnostou VK
AD  - Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. 
      valsamo.anagnostou@yale.edu
FAU - Lowery, Frank J
AU  - Lowery FJ
FAU - Zolota, Vassiliki
AU  - Zolota V
FAU - Tzelepi, Vassiliki
AU  - Tzelepi V
FAU - Gopinath, Arun
AU  - Gopinath A
FAU - Liceaga, Camil
AU  - Liceaga C
FAU - Panagopoulos, Nikolaos
AU  - Panagopoulos N
FAU - Frangia, Konstantina
AU  - Frangia K
FAU - Tanoue, Lynn
AU  - Tanoue L
FAU - Boffa, Daniel
AU  - Boffa D
FAU - Gettinger, Scott
AU  - Gettinger S
FAU - Detterbeck, Frank
AU  - Detterbeck F
FAU - Homer, Robert J
AU  - Homer RJ
FAU - Dougenis, Dimitrios
AU  - Dougenis D
FAU - Rimm, David L
AU  - Rimm DL
FAU - Syrigos, Konstantinos N
AU  - Syrigos KN
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20100509
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Adenocarcinoma/*chemistry/mortality/pathology/therapy
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Large Cell/*chemistry/mortality/pathology/therapy
MH  - Carcinoma, Non-Small-Cell Lung/*chemistry/mortality/pathology/therapy
MH  - Carcinoma, Squamous Cell/*chemistry/mortality/pathology/therapy
MH  - Cell Differentiation
MH  - Cohort Studies
MH  - Connecticut
MH  - Female
MH  - Greece
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*chemistry/mortality/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-2/*analysis
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Up-Regulation
PMC - PMC2875218
EDAT- 2010/05/13 06:00
MHDA- 2010/08/17 06:00
PMCR- 2010/05/09
CRDT- 2010/05/13 06:00
PHST- 2009/08/24 00:00 [received]
PHST- 2010/05/09 00:00 [accepted]
PHST- 2010/05/13 06:00 [entrez]
PHST- 2010/05/13 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
PHST- 2010/05/09 00:00 [pmc-release]
AID - 1471-2407-10-186 [pii]
AID - 10.1186/1471-2407-10-186 [doi]
PST - epublish
SO  - BMC Cancer. 2010 May 9;10:186. doi: 10.1186/1471-2407-10-186.